SEC EDGARSEP 151 min read$COO

Rosebrough Walter M Jr purchased $542K of COO (indirect holdings)

Rosebrough Walter M Jr purchased 10,000 indirectly-held shares of COOPER COMPANIES, INC. (COO) at an average of $54.16 ($54.11–$54.29, $0.54M total) across 2 trades over 2026-09-11 to 2026-09-14.

Original reporting

SEC EDGAR · Rosebrough Walter M Jr

Published Sep 15, 2026, 8:56 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 15, 2026, 9:04 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$COO

Neutral

medium confidence

Mentioned

$COO

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$COONeutralLow

Why it matters

The insider purchase adds a modest bullish signal but is unlikely to move the stock materially.

Market read

Primary source filing with limited trading relevance.

What to watch

Potential upcoming corporate actions not disclosed may influence insider behavior.

Relevance 6/10Novelty 5/10Timing: immediately after Form 4 filing

Background

Cooper Companies (COO) is a medical device and health services firm.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$COONeutralMedium confidence

Context

Director Walter M. Rosebrough Jr purchased 10,000 shares for $541,640, increasing his holding to 20,000 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Purchase size is modest relative to market cap; typical for 10b5-1 plans.

Market effects

Sector

None significant for the healthcare services sector.

Regional

No regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The purchase could be routine and not indicative of future performance.

Key entities

Director
Walter M. Rosebrough Jr
Insider who bought shares.

Read at source ← All news

OCT 27

$COOLow

CooperCompanies CEO steps down (COO:NASDAQ)

CooperCompanies (COO) announced Albert White III stepped down as CEO and board member. Walter Rosebrough Jr. was appointed executive chair. COO is a medical device company.

seekingalpha.com1 min

OCT 27

$COOMed

CooperCompanies names Walt Rosebrough executive chair, CEO steps down

CooperCompanies (COO) announced Walt Rosebrough as Executive Chair, replacing Albert White III as CEO. Rosebrough, former STE CEO, will lead until a permanent replacement is found. The company also announced board changes and reaffirmed its fiscal 2026 guidance. White will serve as a strategic advisor until April 2027.

investing.com1 min

OCT 7

$SYKMed

Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTech

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

tradingview.com3 min

SEP 24

$COOMed

CooperCompanies (COO) Keeps CooperSurgical and Expands Buybacks. What Did the Strategic Review Reveal?

CooperCompanies (COO) reported 1% revenue growth and 4% EPS increase in Q3. The company completed a strategic review, deciding to retain CooperSurgical and expand its share buyback program to $3 billion. Operational improvements and cost-cutting measures are planned. Institutional interest slightly increased, with BlackRock as the largest shareholder.

insidermonkey.com2 min

SEP 21

$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.